Crucell, Harvard to Take Part in Experimental AIDS Vaccine Test
This article is for subscribers only.
Crucell NV plans to test its experimental AIDS vaccine in the U.S. and Africa, advancing the quest for a protective shot against the world’s deadliest infectious disease.
Crucell will participate in a trial of the vaccine in adults who don’t have HIV to assess its safety and ability to prompt an immune response, the Leiden, Netherlands-based company said in a statement today. The company didn’t specify when the trial will start or how many people will be included.